IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Ambey Laboratories IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in New Delhi and caters to Chemical - Pesticides sector. Fast Track Finsec Private is the merchant banker of Ambey Laboratories IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 2nd February 2024.
Ambey Laboratories IPO posted revenues of Rs 120.52 crores and PAT of Rs 7.28 crores in FY24 on annualised basis.Financial results of Ambey Laboratories IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Ambey Laboratories IPO PAT Margin is 6.01%, ROCE (Return on Capital Employed) is 13.14% as per latest financial. The below table shows Ambey Laboratories IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Ambey Laboratories IPO is Rs 171.64 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Ambey Laboratories IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Ambey Laboratories IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Ambey Laboratories IPO is ₹171.64 Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Ambey Laboratories IPO has a Price-to-Earnings (PE) ratio of 23.54 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Ambey Laboratories IPO reported revenue of ₹120.52 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Ambey Laboratories IPO provide insights into sales growth, market demand, and business scalability.
Ambey Laboratories recorded an EBITDA of ₹ 15.35 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Ambey Laboratories Profit After Tax (PAT) is ₹7.24 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 120.37 Cr.
EBITDA Margin:
12.75
%
Net Worth: ₹ 34.13 Cr.
Market Capitalisation:
₹ 171.64 Cr.
P/E:
23.54 times
P/BV: 2.18 times
EV/EBITDA: 12.47 times
Ambey Laboratories operates in Chemical - Pesticides and Manufactures Agrochemical Products For Crop Protection. The Issue is listed on NSE EMERGE in Jul, 2024. Ambey Laboratories IPO size was 44.68 with Issue price of 68.00 .
Merchant Banker(s) of Ambey Laboratories IPO: Fast Track Finsec Private Limited
Ambey Laboratories IPO subscription was 173.18 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Ambey Laboratories IPO listed at a listing price of 89.25 against the offer price of 68.00.
The current market price of Ambey Laboratories is 39.20.
Why Us?
